China A-share innovative drug stocks recover; Qianjin Pharma hits limit up

The intraday reversal in innovative drug names suggests sentiment is stabilizing after recent pressure, with limit-up moves indicating aggressive speculative flows are returning to the sector. This matters because A-share biotech is often a high-beta proxy for risk appetite in the broader market, so the recovery could signal a short-term shift in trader mood beyond just pharma. What to watch is whether the strength broadens beyond a few leaders or remains concentrated in small caps, as that would clarify if this is a genuine sector rebound or a fleeting rotation. The catalyst for the bounce is unclear from the report, leaving the durability of the move as the key open question.